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A B S T R A C T
Microbial diversity plays a key role in the maintenance of intestinal homeostasis and in the development of the
immune system in the gut mucosa. Maybe one of the most important function of our gut microbiota is the
immune system education, in particular the discrimination of friends from foes that occurs during childhood. In
addition to bacterial antigens, several metabolites of microbial origin have a crucial role in training of the
immune system, such as Short Chain Fatty Acids (SCFAs).
There are many evidences on the role of the gut microbiota in rheumatic diseases, in particular modiﬁcations
of microbiota composition causing dysbiosis that, in turn, can induce gut permeability, and thus immunological
imbalance and trigger inﬂammation. In particular, immune cells can reach extra-intestinal sites, such as joints
and trigger local inﬂammation. Childhood is a crucial period of life for development and evolution of the gut
microbiota, especially for the acquisition of fundamental functions such as immunotolerance of commensal
microorganisms. For this reason, gut dysbiosis is gaining interest as a potential pathogenetic factor for Juvenile
Idiopathic Arthritis (JIA). Here we summarized the studies conducted on JIA patients in which a pro-arthrito-
genic microbial proﬁles has been observed; this, together with a depletion of microbial biodiversity, clearly
distinguish patients' from healthy subjects' microbiota. Further studies are however needed to better clarify the
role of microbiota in JIA pathogenesis.
1. Introduction
The gastrointestinal tract is the district that hosts the greatest
number of microorganisms: an estimate of about 100 trillions (10ˆ14), a
number 10 times higher than the cells of the human body (10ˆ13). The
microbiota brings our idea of “human genome” to a new scale, in fact,
quantitatively, the genes of the intestinal microbiota exceed about 100
times the number of genes of the human body. We can say that our
biochemical functions are not only the result of the action of our genes,
but also that of “our” microorganisms, so we have to study both our
genome and our “metagenome” that represents the set of genes of our
microbiota. Speciﬁcally, the bacterial population inhabiting the human
gastrointestinal tract consists of more than 500 bacterial species be-
longing to four main phyla: Firmicutes and Bacteroidetes, representing
almost 80–90%, while Proteobacteria and Actinobacteria about
10–20%; then there are a small part of the Archaea methanogens
(mainly Methanobrevibacter smithii), eukaryotes (especially the yeasts)
and viruses (for example phages). Thus, we are superorganisms and the
microbiota is an organ, actually a “super organ”.
2. The microbial community: from infancy to adulthood
For several years, it was believed that humans were sterile before
birth. Recent studies have instead described that meconium of healthy
newborn infants contains a simple microbial community, dominated by
genera such as Escherichia-Shigella, Enterococcus, Leuconostoc,
Lactococcus and/or Streptococcus [1–3]. The formation of the ﬁrst mi-
crobial community is strictly dependent from mode of birth, which can
substantially inﬂuence the composition of the neonatal gut microbiota.
Children who are delivered spontaneously present an initial simpliﬁed
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gut microbiota similar to that of the mother's vaginal tract, dominated
by Lactobacilli. Instead, children born by Caesarean section present a
gut ecosystem populated by genera such as Staphylococcus, Cor-
ynebacterium and Propionibacterium, very similar to the microbiota of
the mother's skin [4,5].
Immediately after birth, the human intestine is soon colonized by a
series of microorganisms, with the ﬁrst colonizers being facultative
anaerobic bacteria; the newborn gut is an environment suitable for the
colonization of strictly anaerobes, such as Bacteroides, Clostridium and
Biﬁdobacterium spp.. During the ﬁrst months of life, the intestinal mi-
crobiota is therefore characterized by a low richness, with a dominance
of Actinobacteria and Proteobacteria phyla. Subsequently the micro-
biota becomes more complex with greater biodiversity, determined by
the increase of Firmicutes and Bacteroidetes phyla [6–8]. Many factors
inﬂuence the microbial colonization of the gastrointestinal tract; among
these, genetics, gestational age, mode of birth, diet during the ﬁrst
months of life (breast milk or formula), and last but not least en-
vironmental factors, such as hygiene and possible antibiotic treatment
[9,10].
During the ﬁrst year of life, as a result of the increase in food variety
and environmental exposures, microbial biodiversity increases, and so
the complexity of the gastrointestinal microbiota too [11,12]. Child-
hood is a fundamental moment of development and evolution of the gut
microbiota, especially for the acquisition of physiological functions.
The infant gut microbiota seems to be specialized for the acquisition of
nutrients in particular vitamin B and amino acids [12].
The ﬁrst three years of life represent the most critical period for the
growth and development of the child. In fact, changes of the diet (in-
troduction of new food) and consequently intestinal microbiota mod-
iﬁcations have the potential to deeply inﬂuence the health and host
development [4,13–15]. It has been observed that the microbiota of a 3
year old child is 40%–60% similar to that of a healthy adult, reaching a
microbial composition in the adolescence comparable to that of an
adult [4]. Although the gastrointestinal microbiota of children and
adolescents contains many of the same taxa present in adults, sig-
niﬁcant diﬀerences have been reported in the proportions of Bacteroides
and Biﬁdobacterium spp., as well as members of the Clostridia class, and
it has now been demonstrated that the adult intestinal microbiome
remains stable from the third to the seventh decade of life [16].
Factors aﬀecting the stability and complexity of intestinal micro-
biota over time, from infancy to adulthood to the elderly include ge-
netics, birth mode, diet, geography, hygiene, stress, medications. Some
of these factors may introduce perturbations leading to phenomena of
microbial dysbiosis. This disturbing event introduces the concept of
“resilience” which refers to the amount of perturbation that a microbial
system can tolerate and the ability to restore the state of equilibrium
[17]. In the healthy gut, biodiversity, resilience and stability contribute
to important physiological processes including protection against pa-
thogens and education of immune system [18].
3. Host-microbes co-evolution, intestinal homeostasis and
dysbiosis
Human beings, like all animals, represent a complex structure in
which various microbial ecosystems are established in the various dis-
tricts of the body (e.g. skin, vagina and intestine). The intestine is the
most densely populated district by microorganisms (10ˆ14 bacteria).
During evolution, changes in length and the partitioning of the diges-
tive tract allowed vertebrates to occupy diﬀerent habitats and exploit
diﬀerent nutritional strategies. Many of these changes in bowel phy-
siology have been driven by the need to optimize basic physiological
and biological functions, such as nutrient uptake [19]. The animal and
human host and their microbiota have evolved over the millennia in a
homeostatic and symbiotic relationship. The normal functioning of the
digestive and immune system depends on the presence of non-patho-
genic “beneﬁcial” bacteria and the homeostasis of the intestinal
microbiota is characterized by the coexistence of various commensal
microbial species.
The “healthy” status is represented by a high level of intestinal
microbial richness, while the disease status is characterized by the
massive reduction of intestinal microbial species, as observed in several
inﬂammatory and autoimmune diseases [20,21]. In an ecological con-
text, biodiversity creates an ecosystem able to resist to perturbations
deriving from the external environment [22]. In fact, competitive in-
teractions between microbial species can help to maintain the stability
of the intestinal microbiota [23]. Understanding how the “healthy”
microbiota gives rise to a stable and resilient state would allow stra-
tegies to increase resilience in disease conditions.
4. The microbiome and immune training
Microbial diversity plays a key role in the maintenance of intestinal
homeostasis and in the development of the immune system in the gut
mucosa. Maybe one of the most important functions of our microbiota
is the immune system education, in particular the discrimination of
friends from foes. In addition to bacterial antigens, several metabolites
of microbial origin have a crucial role in training of the immune system,
such as Short Chain Fatty Acids (SCFAs). SCFAs are known as fuel for
colonocytes, but provide important immune protective functions. For
example, acetate was found able to regulate intestinal homeostasis, by
stimulation of the proliferation of Treg cells in the lamina propria [24],
and butyrate have several immunological functions associated to potent
regulatory eﬀects on gene expression, promoting epithelial barrier in-
tegrity [25].
Regarding correlation between gut microbiome and immune re-
sponsivity, some studies showed important new insights on underlying
molecular eﬀects of the microbiome on immune responses [26], the
role of environmental and genetic factors on T and B cell immune traits
[27] and genetic and host/environmental factors inﬂuencing cytokine
responses [28,29]. Combining large-scale analysis of immune varia-
bility with accompanying functional information allows examination of
immunity at an unprecedented level. These studies provide for the ﬁrst-
time insights and reference values for future studies addressed at un-
derstanding how the microbiome aﬀects (the interaction between) in-
ﬂammation and autoimmune disorders and how the metabolome is
involved in this interaction.
The breaking of the microbial balance generates intestinal dysbiosis,
characterized by an altered composition of the microbial populations
with consequent continuous immunological stimulation that leads to
abnormal immune responses that often originate an inﬂammatory
status. Dysbiosis has been described in many gastrointestinal diseases,
such as inﬂammatory bowel diseases (IBD), celiac disease, irritable
bowel syndrome (IBS), antibiotic-associated diarrhea, tropical entero-
pathy and many others [30–33]. Recently, numerous evidences suggest
that the intestinal dysbiosis is not limited to gastrointestinal diseases,
suggesting that intestinal bacteria can inﬂuence the systemic immune
response. In fact, studies have shown intestinal dysbiosis in relation to
metabolic syndromes (obesity, diabetes), chronic periodontitis, vagi-
nosis, atopic diseases, rheumatic diseases, Alzheimer's disease, autism
and others [34–37]. The loss of a correct homeostasis of the intestinal
immune system, together with the increased intestinal permeability,
have been reported to be closely correlated with alterations of the
microbiota that make the host more susceptible to the onset of in-
testinal diseases [38]. During aging, processes of chronic inﬂammation
are characterized by loss of gastrointestinal function, alteration of host
immune response and consequent chronic gut inﬂammation. The
characteristics of an unbalanced microbiota include an increase in
gram-negative bacteria linked to an environment with high oxidative
stress, with inﬂammation and production of pro-inﬂammatory meta-
bolites. Often these variations appear to be diet-dependent and strongly
correlated with health indicators, including susceptibility markers, as
well as inﬂammation markers [39].
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However, while disruption of intestinal homeostasis can be widely
recognized, it is not clear whether dysbiosis represents a cause or a
consequence of the disease. Several studies have shown diﬀerential
factors contributing to dysbiosis, including host genetics (mutations in
genes involved in intracellular recognition of microbes, such as the
NOD2 gene, or in genes related to regulatory or pro-inﬂammatory im-
mune responses), lifestyle (diet, stress, hygiene), exposure to micro-
organisms and pharmacological treatments, such as antibiotics.
Mutations in genes involved in mechanisms of immune regulation or in
the pro-inﬂammatory pathways could lead to uncontrolled inﬂamma-
tion in the gastrointestinal tract. In presence of dysbiosis, there is an
abnormal composition of the microbiota, which often results in a re-
duction in the number of symbionts and/or an increase in the number
of pathobionts. The result is a nonspeciﬁc inﬂammation that can pre-
dispose the genetically susceptible individual to disease states char-
acterized by inﬂammatory responses mediated by T-helper cells [40]. It
is also hypothesized that inﬂammation alone inﬂuences the composi-
tion of the microbiota favoring the pathobionts [40].
A healthy microbiota contains a balanced microbial composition
characterized by symbiotic bacteria carrying beneﬁcial functions to the
host such as commensal bacteria and permanent residents, that do not
bring any beneﬁt or harm to the host, as well as pathobiont bacteria,
permanent bacteria with pathogenetic potential, but strictly under
control of the symbionts and the host. During the dysbiosis, however,
the number of symbionts decreases, while the number of pathobionts
increases [40]. Furthermore, hygiene and excessive use of antibiotics,
unable to distinguish between pathogenic or symbiotic/commensal
microorganisms, could negatively aﬀect the microbiota [40]. In this
context, the “old friends” hypothesis proposed in 2003 by Rook et
coworkers [41] and the “Hygiene hypothesis” [42] can explain the
relationships between microbial exposure and development of auto-
immune diseases. The “old friends” hypothesis refers to those micro-
organisms that evolved together with the human immune system, in the
Paleolithic era, at the time of hunter-gatherers, and that therefore in-
ﬂuenced the evolution and development of the human immune system
[43].
The “hygiene hypothesis” (also called the “theory of biome deple-
tion” and the “lost friends theory”) states that the reduction of im-
portant microbial patterns necessary to educate the host's immune
system results in a decrease in intestinal microbial richness with con-
sequent alterations in processes involving host-microorganism interac-
tions, capable to promote the onset of disease in susceptible hosts
[42,43]. Therefore, a sterile environment or excessive hygiene, typical
of Western developed countries, allows us to protect against exposure to
dangerous pathogens, but at the same time to avoid exposure to so-
called “old friends” [44–46].
Many subjects living in traditional rural communities are con-
tinuously exposed to a number of deadly infectious diseases, such as
malaria or gastrointestinal or respiratory tract infections. These infec-
tions may have a chronic eﬀect on inﬂammation, as it has recently been
shown that brief stimulation of monocytes to microbes induces a pro-
longed hyper-inﬂammatory state, which has been named trained im-
munity, and which is mediated by profound reprogramming of the in-
tracellular metabolism and epigenetic reprogramming [47]. Alterations
in trained immunity processes could set important stages in auto-
immune disorders.
A limited exposure makes the immune system immature, especially
during childhood and can promote the development of allergies and
autoimmune diseases, while early exposure to ancient environmental
microorganisms, the so-called “old friends”, is essential to “train” our
immune system, preventing the attack of non-legitimate targets that is
the starting event of autoimmune disorders.
5. The impact of diet on the intestinal microbiota
Numerous studies have shown that the mutual relationship between
the intestinal microbiota and the host is strongly inﬂuenced by the diet.
The consumption of various nutrients in fact aﬀects the composition
and structure of microbial communities as it provides substrates for
microbial metabolism itself.
From childhood, the biggest change in the composition of the mi-
crobiota occurs when solid food is introduced. At weaning, a shift to-
wards a more stable microbiota was observed, similar to that of an adult
[11]. In this period of life, the concept of association between diet,
commensal bacteria and health can be introduced. Numerous studies
have described diﬀerences in the composition of the gut microbiota in
formula or breastfed infants [48–50].
In human milk, there are important bioactive compounds, in par-
ticular the indigestible oligosaccharides such as fructooligosaccharides
(FOS) and galacto-oligosaccharides (GOS) that contribute to the ab-
sorption and digestion of nutrients, to the immune protection and to the
selective promotion of the growth of the Biﬁdobacterium genus
[48,49,51–53]. Biﬁdobacterium is linked to the fortiﬁcation of the in-
testinal mucosal barrier, to the protection against pathogens and to the
modulation of the intestinal immune system [54–56]. Another diﬀer-
ence is that aerobic microorganisms appear to be more prevalent in the
feces of breast-fed infants, whereas the facultative anaerobic and
anaerobic microorganisms, which preferentially use anaerobic glyco-
lysis, are more commonly found in the feces of formula-fed infants [11].
The diﬀerent food sources have therefore guided the evolution of
human beings where co-evolution with symbiotic microorganisms has
given rise to genuine mutualistic relationships. A comparison between
the intestinal microbiota between diﬀerent primates and mammals has
shown that humans are grouped together with omnivorous primates
compared to non-primate species [19], suggesting how the variety of
foods in an omnivorous diet is the most important factor of the gut
microbiota evolution.
Signiﬁcant variations in the composition of the microbiota have
been associated with the consumption of dietary ﬁbers of fruits and
other vegetables, compared to a diet rich in animal proteins, simple
sugars and lipids. In controlled dietary experiments in healthy volun-
teers, variations in the intake of resistant starches or non-starch poly-
saccharides have been linked variations of speciﬁc bacterial taxa, such
as Ruminococcus bromii and Eubacterium rectale [57]. By in vitro analysis
of human fecal samples, these taxa have been shown to selectively
metabolize speciﬁc substrates consisting of indigestible carbohydrates
[58]. The model systems have in fact shown that an important function
of the microbiota of the intestine consists in its ability to ferment
complex carbohydrates and polysaccharides, with the consequent pro-
duction of SCFAs [59]. Additional sources of glycans for the metabolism
of the intestinal microbiota are also represented by the mucus at the
level of the intestinal mucosa produced by the host.
In recent years, thanks to studies carried out on diﬀerent popula-
tions all over the world in non-urbanized environments, it has been
possible to understand the role of diet in determining the composition
of the intestinal microbiota. In several studies fecal microbiota from
traditional populations living in rural, non-industrialized societies were
compared with that of populations characterized by a typically Western
lifestyle [12,60–64].
Our study [60] showed for the ﬁrst time that the intestinal micro-
biota of children living in the African rural village of Burkina Faso was
completely diﬀerent from the microbiota of children living in Italy, as
representative of a modern Western country. By using the Next Gen-
eration Sequencing technique, we analyzed the composition of the in-
testinal microbiota of healthy children aged 1–6 years who live in a
rural African village in Burkina Faso, whose life conditions are very
similar to those of Neolithic. The diet of these children is mainly ve-
getarian, consisting of cereals such as millet, sorghum, vegetables and
legumes. The results were compared with those obtained from a po-
pulation of Italian children of the same age having a typically Western
diet. The microbiota of children from Burkina Faso have greater bio-
diversity compared to Italians, especially bacteria that are able to digest
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cellulose (Prevotella, Xylanibacter, Butyrivibrio and Treponema). These
bacterial genera allow to maximize the extraction of energy from non-
digestible food polysaccharides, and return beneﬁcial compounds for
our intestines, such as SCFAs, in particular butyrate, a powerful natural
anti-inﬂammatory. Moreover, despite the fact that these children live in
precarious hygiene conditions and are subject to a high rate of in-
fectious diseases, they present a reduced number of potentially patho-
genic bacteria, such as Escherichia coli/Shigella, which are instead pre-
sent in the feces of Italian children.
Furthermore, we have also shown how feeding is responsible for the
composition of microbiota; in fact, children of 1–2 years old still
breastfed, belonging to both populations, showed a similar microbial
proﬁle with a predominance of Biﬁdobacterium.
Subsequently, other studies demonstrating the impact of diet on the
intestinal microbiota were conducted on geographically isolated po-
pulations residing in Amazonian regions (Venezuela), rural Malawi
populations [12], and on Bangladeshi children [65], as well as a study
of populations of Papua New Guinea in comparison with residents of
United States of America [63]. An interesting work carried out on the
last hunter-gatherer populations, the Hazda from Tanzania, re-
conﬁrmed how the diet plays a key role in the determination of the
intestinal microbial structure and how speciﬁc microbial proﬁles are
acquired with speciﬁc metabolic functions [62].
In order to understand how long the diet is able to modify the
composition of the intestinal microbiota, David and coworkers [66],
performed a study on 10 volunteers who followed a strictly vegetarian
diet for 5 days, moving then on to a strict carnivorous diet in the 5 days
later. Interestingly, in 24–48 h the composition of the microbiota
changed signiﬁcantly: during the vegetarian diet, bacterial species able
to ferment complex carbohydrates prevail, while during the diet based
on animal proteins bacterial species are selected, such as Bilophila
wadsworthia, able of metabolizing proteins and toxic compounds de-
riving from the burning of meat, which have a well-known strong pro-
inﬂammatory potential.
More recently, our study on Burkina Faso populations [61] has ex-
amined the eﬀect of diet, environment and lifestyle when people move
from a rural environment to urban areas, experience improved socio-
economic conditions and are exposed to a “globalized” Western type
diet. Once again, we have shown that urbanization and changes of
dietary habit play a role in shaping gut microbiota, independently to
ethnicity. Furthermore, we demonstrated that ancient microorganisms,
especially ﬁber-degrading bacteria, are at risk of being eliminated by
the fast-paced globalization of foods and by the advent of westernized
lifestyle. Thus, these results can help to understand the role of micro-
biota in the epidemiology of non-communicable diseases.
In addition, the diet has also been associated with other types of
intestinal microorganisms, such as Archaea and fungi [67,68]. For ex-
ample, carbohydrate consumption is associated with the abundance of
Methanobrevibacter [68]. This archaeon can increase the production of
gas and SCFAs by metabolizing hydrogen by fermentation of carbohy-
drates, and thus playing an anti-inﬂammatory role [69]. Likewise, the
diet could also inﬂuence intestinal fungal communities, which have
been associated with the pathogenesis of IBD. Evidence has shown that
alteration of immune response to fungi could contribute to chronic
inﬂammation, as occurs in Crohn's disease [70–72].
Moreover, the MetaHIT Consortium proposed to categorize the in-
testinal microbiota in “enterotypes” [73]. People can be classiﬁed as
having a predominance of Prevotella, Bacteroides or Ruminococcus in the
intestinal microbiota. These enterotypes were related to a diet rich in
animal protein and fat (Bacteroides) and a diet rich in carbohydrates and
simple sugars (Prevotella) [74]. There has been considerable discussion
about enterotypes; some data sets support the existence of these cate-
gories, while others do not [17], suggesting that the detection of en-
terotypes depends on the computational approach used to analyze data
sets [75]. It is suggested that a better term could be “enterogradient”,
based on the dominance of Bacteroides or Prevotella. It seems that these
two genera largely do not exist in equal proportions in the human gut
[76]. A larger proportion of Prevotella in the human intestinal micro-
biota could be considered a marker of rural or traditional culture, while
a higher percentage of Bacteroides is associated with industrialized
countries [73]. Overall, these studies demonstrated the co-evolution
between diet and microbiota in rural areas and urban societies, showing
the eﬀect of Westernization on the loss of traditional microbes
[60,66,74,77] and supporting the hypothesis of a consequent depletion
of bacterial wealth in relation to metabolism (obesity, insulin re-
sistance, dyslipidemia) and inﬂammatory disorders.
6. Alterations to the gut microbiota induced by antibiotic
treatment
Several concerns have risen from the antibiotic use in treating pa-
thogenic infections, due to the capability of alteration of the diversity
and functional capacity of the dominant gut microbiota [78,79]. Al-
though beneﬁts that antibiotics have brought to medicine are un-
discussed, their use represents an example of environmental pressure on
resident microbiota, able to largely disrupt the microbial environment,
promote secondary infections by opportunistic pathogens and spread
antibiotic resistance. In fact, antibiotics do not selectively target pa-
thogens, but they also unavoidably aﬀect the viability of non-patho-
genic and resident species that contribute to host health.
For example, Dethlefsen and coauthors [80] describe how cipro-
ﬂoxacin treatment inﬂuenced the abundance of a third of the gut bac-
terial taxa, decreasing the taxonomic richness, diversity, and evenness
of the community, though inter-individual variation in the response to
this antibiotic was observed. Others antibiotics, such as ﬂuor-
oquinolones and β-lactams, administrated for seven days, were re-
sponsible of signiﬁcantly decreasing microbial diversity and the core
phylogenetic microbiota [81]. Moreover, in infants, combination of
ampicillin and gentamicin for 4 weeks induced a signiﬁcant increase of
Proteobacteria and reduction of Actinobacteria compared to an un-
treated group [82].
Intergenerational transmission of bacteria during birth initiates the
natural successional development of the intestinal microbiota in all
mammals. Aloisio and collaborators [83] evaluated the eﬀects of in-
trapartum antibiotic prophylaxis (IAP) on gut microbiota of newborn,
routinely used in a group B Streptococcus positive-women to prevent
the infection of infants. The authors found signiﬁcant diﬀerences in the
microbial composition of neonates born to mothers who had received
IAP, with a lower abundance of Actinobacteria (in particular Biﬁdo-
bacterium spp. strains) and Bacteroidetes, as well as an over-
representation of Proteobacteria.
Korpela and collaborators [84] indicate that it is possible to correct
undesired changes in microbiota composition and function caused by
antibiotic treatments in infants by supplementation of a probiotic
mixture together with at least partial breastfeeding.
More recently, Tulstrup et al. [85] demonstrated that the develop-
ment of the gut microbiota can be disrupted by antibiotic exposure,
potentially aﬀecting early-life microbiota-dpendent metabolic pro-
gramming. In particular, the authors demonstrated that in animal
model early-life exposure to an antibiotic-perturbed and low-diversity
microbiota is suﬃcient to cause changes in body weight persisting into
adulthood.
Only recently it was appreciated the role of microbiota on host
physiology and the associations between antibiotic use and numerous
diseases. Antibiotic treatment may disrupt microbe–microbe, as well as
microbe–host interactions that represent key mechanisms for the
maintenance of homeostasis within this ecosystem. Commensal bac-
terial communities confer protection to the host through the inhibition
of growth of pathogenic bacteria and competition for ecological niches,
and through stimulation of host immune system that enhances its an-
timicrobial activity. Direct inhibition of pathogen expansion by com-
mensal bacteria can derive by: (i) competition for nutrients, (ii)
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production of antimicrobial peptides and toxins, (iii) stimulation of host
defense mechanisms [86,87].
In a review of Arvonen and coworkers [88], overview of human
studies evaluating long-term changes to the microbiota following ex-
posure to antibiotics was described. Although methods of investigation
of gut microbiota alteration were diﬀerent among the studies, in many
instances it resulted that antibiotics do impact the microbiota long-
term, even up to two years [87], and it seems that antibiotics directed
against anaerobic microorganisms have a lasting impact than others.
Expansion of pathogenic microorganisms can be suppressed by the
presence of surrounding commensal populations that compete for si-
milar nutrient sources. The expansion of antibiotic-resistant strains
and/or the acquisition of antibiotic resistance can contribute to per-
manent alterations of the microbiota composition, potentially leading
to loss of beneﬁcial and/or increase of deleterious species. Moreover,
reduced stimulation of the immune system by commensal bacteria
could damage the correct education/training of the immune system,
leading to the development of immune responses against self or
harmless antigens, thus predisposing the host to autoimmunity.
Atopic, inﬂammatory and autoimmune diseases have been linked to
gut microbiota dysbiosis [89–93] and, in some cases, signiﬁcant asso-
ciations have been found between antibiotic use and these diseases
during early life, a critical period for maturation of the immune system
and establishment of immunological tolerance [94,95]. Despite the
relative paucity of data related to antibiotic exposures and autoimmune
disorders, some studies showed that the number of courses of anti-
biotics administered during childhood is associated with risk of juvenile
rheumatoid arthritis [96,97] and of inﬂammatory bowel disease [98].
In the review of Arvonen et al. [88], the coauthors also analyzed the
two registry-based case controls studies [96,97] on JIA patients and
healthy controls with the aim to evaluate whether antibiotic use aﬀects
subsequent risk of JIA, and performed a regression analysis of the data,
observing that exposure to diﬀerent antibiotic categories seems to be
associated to higher risk of JIA compared to exposure to a limited
number of antibiotics. One of the main objectives of scientiﬁc research
in pediatric dysbiosis will be to understand how broad spectrum of
antibiotic usage in children may disrupt normal development of the gut
microbiota, and consequently the immune system, potentially leading
to increased risk of inﬂammatory and autoimmune diseases.
7. The gut microbiota and autoimmune diseases
In economically developed countries, a progressive increase of
metabolic, inﬂammatory and autoimmune diseases, such as obesity,
type I diabetes, inﬂammatory bowel disease (IBD), allergies, multiple
sclerosis, autism, arthritis and rheumatic diseases, have been recorded,
particularly in pediatric populations. Modern lifestyles, in particular
“Western” diet (high-fat/high-sugar diet), processed and reﬁning food,
urbanization, pollution, sanitation and antibiotic treatment have mod-
iﬁed the gut microbiota composition and related metabolic functions,
with respect to diet and lifestyle and gut microbial proﬁles of tradi-
tional and isolated populations worldwide [60,61,66,99–104].
Evidence showed that loss of beneﬁcial symbionts, deriving by
dysbiotic microbiomes, predispose to non-communicable diseases
[63,105–107]. In the last decade, alteration of gut microbiota was ob-
served in rheumatic disease and arthritis, most notably rheumatoid
arthritis (RA), psoriasis, and the related spondyloarthritides (SpA), in-
cluding ankylosing spondylitis (AS) and reactive arthritis (ReA), simi-
larly to IBD, in which gut bacteria have a role in the etiopathogenesis
[104,108,109]. In early life, some studies showed that artiﬁcial feeding
is associated with an increased risk of autoimmune disease, such as
ankylosing spondylitis (SpA) [110]. While, breast-feeding appears to be
protective against JIA, as showed in some studies involving JIA children
and healthy subjects [111–113].
The intestinal microbiota can modulate either local mucosal im-
mune system or inﬂuence the systemic immune response. Of great
interest is the understanding if dysbiosis is as a trigger or a reﬂection of
autoimmune and inﬂammatory disorders [114,115].
Studies in germ-free (GF) and speciﬁc pathogen-free (SPF) animal
models [116,117], together with a wide body of literature on eﬀect of
administration of antibiotics [118] or probiotics in modulation of gut
microbiota, and recently the fecal microbiota transplantation model
[119,120] have highlighted the role of the microbiota in immune
homeostasis. In particular, microbial communities have the potential to
shape the innate and adaptive immune responses [121–124].
In animal models, mice reared in germ-free conditions are healthy,
the introduction of some bacterial species can have inﬂammatory or
anti-inﬂammatory eﬀect directly promoting on inhibiting the develop-
ment of inﬂammatory disease, such as autoimmune disease or IBD. It
was hypothesized that, during intestinal inﬂammation, increased mu-
cosal uptake of gut bacteria and their membrane molecules, such as
Lipopolysaccharides (LPS), peptidoglycan-polysaccharides (PG-PS) lead
to systemic diﬀusion of these bacterial components and subsequent
extra-intestinal inﬂammation, such as arthritis [125]. This hypothesis
was also supported by historical studies showing reactivation of ar-
thritis by systemically injected LPS or PG-PS [126,127] and the
founding of bacterial antigens, such as that of Yersina spp. and Salmo-
nella spp., within synovial leukocytes in patients with B27-associated
reactive arthritis [128,129].
Some studies demonstrated that, not necessarily pathogenic bac-
teria, but also gut microbial communities are suﬃcient to induce joint
inﬂammation [122,130]. For example, Rath and collaborators [122]
identiﬁed subpopulations of intestinal bacteria playing a crucial role in
the pathogenesis of spontaneous colitis and peripheral arthritis in ge-
netically susceptible B27 transgenic rats. In particular, in animal
models of arthritis, upon germ-free conditions, the re-introduction of
Bacteroides spp., especially B. vulgatus and B. fragilis, reactive articular
inﬂammation [122,131]. Recently, mice colonized with Prevotella copri,
a bacteria species found abundant in new onset RA patients, showed
increased sensitivity to dextran sodium sulfate (DSS)-induced colitis
and increased inﬂammation [132].
Moreover, in autoimmune and inﬂammatory diseases, the gut mi-
crobiota can induce alteration of mucosal permeability and reduction of
immune tolerance to commensals [123,133–135]. Tailford and collea-
gues [136] showed that Bacteroides spp. and Akkermansia muciniphila
were able to increase access of the bacteria to the intestinal immune
system, promoting inﬂammatory processes. The former bacterial genus,
thanks to enterotoxin production [137], and, the latter, through mucin
degradation, can increase mucosal permeability and internalization of
enteric bacteria in the mucosa [138–140]. Along those lines, increased
intestinal permeability has been found both in JIA patients [40] and in
adults with ankylosing spondylitis [141].
The gut microbiota also plays an important role in the adaptive
immune system. An animal model of spontaneous arthritis, the K/BxN
mouse, explained the potential role of the microbiota and the missing
links with systemic immunity and autoimmune arthritis [116]. K/BxN
mice reared in GF conditions showed reduction of arthritis. Commensal
bacteria can induce lamina propria Th17 cells and activate inﬂamma-
tion on the joints by migration of T cells into the peripheral lymphoid
tissue [142]. Secretion of IL-17, in turn, acts directly on B cells to in-
duce production of autoantibody that, ﬁnally, lead to the development
of disease. It was reported that segmented-ﬁlamentous bacteria (SFB)
into GF K/BxN mice drive autoimmune arthritis through induction of
the Th17 cells [116].
Therefore, although it was hypothesized that gut bacteria induce
systemic immune response through soluble factors circulating from the
gut into the periphery, the study on K/BxN mice showed that micro-
biota-derived products could inﬂuence the immune system at distal
sites without leaving the gut. Thus, T cells whose functions are dictated
by intestinal commensal bacteria can be eﬀectors of pathogenesis in
tissue-speciﬁc autoimmune disease.
As mentioned above, diet is one of the main factor contributing to
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modulation of gut microbiota composition.
Some disorders, such as celiac disease and obesity, have an evident
association with diet and with triggering of arthritis and rheumatic
disease [143,144]. Evidences on the role of the gut microbiota in
rheumatic diseases lead to suppose that diet, aﬀecting the microbiota
composition, in turn, can inﬂuence these disorders [145,146].
A great body of literature showed that changing of dietary habits
and lifestyle led to modiﬁcations of microbiota composition, causing
dysbiosis that, in turn, can induce gut permeability, and thus im-
munological unbalance and trigger of gut inﬂammation. In arthritis
condition, immune cells can reach extra-intestinal sites, such as joints
and trigger local inﬂammation (Fig. 1) [147,148].
8. Altered microbial proﬁles in juvenile idiopathic arthritis
Pediatric rheumatic diseases consist of a heterogeneous group of
autoimmune conditions, most of which are chronic systemic illnesses
that can determine serious morbidity and long-term disability [149].
The pathogenesis of rheumatic disorders is still under investigation, and
currently it is believed to originate from a complex interaction between
host genetics, immunological dysregulation and environmental inﬂu-
ences [149]. Intestinal microbiota aﬀects many physiological processes,
having a regulatory eﬀect on intestinal permeability and a modulatory
eﬀect on host immune system and self-tolerance acquisition [150]. As
above showed, altered composition and function of gut microbiota are
deemed to play an important role in the development of many auto-
immune chronic diseases, including Inﬂammatory Bowel Diseases (IBD)
[151,152], Type 1 Diabetes [92,153] and chronic arthritis, such as
rheumatoid arthritis (RA) and ankylosing spondylitis (AS) [132,154]. In
the ﬁeld of Pediatric Rheumatology, gut dysbiosis is gaining interest as
a potential pathogenetic factor for Juvenile Idiopathic Arthritis (JIA).
JIA is the most common chronic rheumatic disease of childhood,
with a reported prevalence between 16 and 150 per 100.000 [155]. The
term JIA does not refer to a single disease but rather encompasses a
group of related conditions characterized by chronic joint inﬂammation
and variable systemic involvement [155].
According to current classiﬁcation [156], there are seven diﬀerent
JIA categories: oligoarticular (involving less than 4 joints at onset);
polyarticular (involving more than 4 joints at onset) rheumatoid factor
positive and negative; psoriatic; enthesitis related arthritis (ERA); sys-
temic onset JIA; undiﬀerentiated arthritis. Picco and coworkers [157]
have indirectly suggested a potential role of intestinal dysregulation in
JIA, demonstrating an increased gut permeability in JIA patients.
Moreover, an association between antibiotic use and development of
JIA has been proven and may be related to alteration in host microbiota
[96,97].
In the era of Next Generation Sequencing, studies have focused on the
composition of fecal microbiota in a particular subset of JIA- ERA, as
summarized in Table 1. ERA accounts for 10–20% of JIA and it is
considered the equivalent of adult SpA. Clinically, it is characterized by
the association of arthritis of large joints in lower extremities, entheses
inﬂammation and common involvement of sacroiliac joints and axial
skeleton [155]. ERA shows strong correlation with the presence of
Human Leukocyte Antigen-B27 (HLA-B27) and with a family history of
HLA-B27 related diseases, namely AS, acute anterior uveitis, sacroiliitis
related to IBD [156]. Interestingly, some degree of intestinal in-
ﬂammation is present in almost two thirds of pediatric SpA patients
[158] and, given this association, alteration in fecal microbiota has
been identiﬁed as a potential trigger for ERA that could drive gut and
joint inﬂammation (Fig. 1).
The most of the studies conducted so far and proposing relationships
between gut microbial proﬁles and autoimmune diseases are mostly
associative. Stoll and colleagues [115] evaluated the content of fecal
microbiota in a cohort of 25 children with ERA and 13 healthy controls.
The study demonstrated a decreased presence of Faecalibacterium
Prausnitzii in ERA patients compared to controls, and an increased
abundance of Biﬁdobacterium, mostly B. adolescentis. These ﬁndings are
consistent with previously reported data on IBD patients [159,160], as
well as in other diseases [37] and could suggest some similarities in the
pathogenesis of these conditions.
Moreover, two other bacterial strains, Akkermansia muciniphila and
Bacteroides showed an increased abundance in patients versus controls,
though not statistically signiﬁcant. A. muciniphila is considered a com-
mensal microorganism that does not cause inﬂammatory diseases, but
is able to degrade intestinal mucin, thus increasing intestinal perme-
ability and contributing to arthritic inﬂammation through disruption of
tolerogenic state between the mucosal immune system and intestinal
microbiota [138].
In a recent study of Stoll and coworkers [161], fecal samples were
collected from 30 ERA patients and 19 healthy children, as well as 11
SpA and 10 healthy adults. Decreased levels of F. prausnitzii A2-165
strain were conﬁrmed in ERA patients, and similar trends were ob-
served in SpA adult patients. Findings of Stoll and coworkers suggest
that depletion of F. prausnitzii could play a role in the pathogenesis of
ERA and SpA. As a matter of fact, F. prausnitzii is a producer of SCFAs
including butyrate, a compound with known anti-inﬂammatory and
regulatory eﬀects [162]. Whole Genome Sequencing study by Stoll and
collaborators [161], analyzing the gut microbial communities at func-
tional level, revealed a decreased representation of the butanoate
pathway in microbiota of ERA patients, indicating a decreased capacity
to synthesize this anti-inﬂammatory agent.
Furthermore, Bacteroides levels were similar in ERA children and
controls, but B. fragilis was four times increased in ERA, consistently
with their previous ﬁndings, while opposite trends were described for
Fig. 1. Role of gut microbiota in development of JIA-
ERA. Genetics and environmental factors, diet and life-
style aﬀect the stability and complexity of the gut mi-
crobial proﬁles causing dysbiosis and gut epithelial per-
meability. Dominance of pathobionts could be
responsible of alteration of both microbial community
composition and bacterial functions. Colonization of pa-
thobionts in the gut induce diﬀerentiation of Th17 cells
producing IL-17, which subsequently migrate from the
gut to peripheral lymphoid tissue. IL-17, in turn, acts
directly on B cells promoting diﬀerentiation of germinal
center B cells in systemic organs with production of au-
toantibody that can circulate into target organ joints,
contributing, ﬁnally, to the development or maintenance
of inﬂammation.
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adult patients. Interestingly, Bacteroides abundance was increased in
ERA patients also in an Indian study by Aggarwal and colleagues [163].
Increased Bacteroides in pediatric patients, but not in adults, could
suggest that this bacterial strain plays a role in JIA due to its inﬂuence
on immune system development, as already hypothesized for other
autoimmune pediatric diseases [164]. In their study, Aggarwal and
collaborators also found higher levels of Enterobacteriaceae, especially
Klebsiella genus, consistent with previous data on AS [165], and of
Enterococcaceae, similarly to ﬁndings in IBD mouse models [166].
Moreover, Prevotella was less abundant, but this was likely related to
diﬀerences in diet of the Indian population. In this study, oral probiotic
were administered to a small sample of ERA patients in order to
evaluate possible modiﬁcations in gut microbial proﬁle, but no diﬀer-
ences were identiﬁed after a period of four months of treatment.
Furthermore, in a Finnish work the authors evaluated [167] mi-
crobiota proﬁles of fecal samples from 30 new onset JIA patients, that
were not treated with corticosteroid and disease-modifying anti-rheu-
matic drugs, ﬁnding a lower relative abundance of Firmicutes and higher
presence of Bacteroidetes, especially bacteria belonging to Bacteroides
genus, in JIA, in agreement with the previously discussed results from
Stoll [115] and Aggarwal [163] in JIA-ERA. The authors found also
high abundance of Actinobacteria and Fusobacteria in JIA patients and
Lentisphaerae in controls, suggesting that JIA patients present speciﬁc
microbiota proﬁle.
Table 1
Summary of studies on fecal microbiota proﬁles in JIA in comparison with healthy children and adult SpA and controls.
Cohorts Summary of fecal microbiota proﬁles Findings on gut microbial functional proﬁles References
25 children with JIA-ERA and 13 healthy
subjects from USA
in ERA patients:
- Reduction of Faecalibacterium prausnitzii,
- Increase of Biﬁdobacterium adolescentiis
- Trend of abundance in Akkermansia muciniphila
and Bacteroides
not performed Stoll ML et al.,
2014 [115]
30 new onset JIA patients from Finland in JIA patients:
- Low abundance of Firmicutes and high
abundance of Bacteroidetes (Bacteroides genus).
- High abundance of Actinobacteria and
Fusobacteria.
In controls:
- Trend of abundance of Veillonella, Streptococcus,
Coprococcus, Lachnobacterium and Anaerostipes.
not performed Tejesvi MV et al.,
2015 [167]
29 JIA (19 ERA vs 10 polyarticular-JIA; nERA)
and 29 healthy subjects from Italy
in both JIA subtypes:
- Abundance of Ruminococcaceae compared to
healthy subjects.
in ERA patients:
- Reduction in Clostridiaceae and
Peptostreptococcaceae
- Increase of Clostridium cluster XIVb
in JIA-nERA:
- Increase in Veillonellaceae
- Trend of decrease in Faecalibacterium.
HLAB27 positive patients:
Abundance of Bilophila, Parvimonas,
Oscillibacter.
HLAB27 negative patients:
Abundance of Haemophilus and Eggerthella.
JIA-ERA metagenome was enriched in bacterial
functions related to cell motility, ﬂagellar assembly
and chemotaxis– > promotion of bacterial
migration and invasiveness through mucosal barrier
Di Paola M et al.,
2016 [168]
99 new onset, treatment–naïve JIA patients
from Italy (n= 78) and Holland (n=21)
In Italian JIA children:
- Increase of Erysipelotrichacea, F. prausnitzii,
Parabacteroides, Ruminococcaceae,
Phascolarctobacterium and Dorea.
- Decrease of Allobaculum, Gemellaceae,
Propionibacterium acnes, Enterococcus,
Turicibacter, Blautiaand Barnesiellaceae in Dutch
JIA patients:
- Eggerthella lenta, Rikenellaceae, Coprobacillus
and Mogibacteriaceae discriminate from healthy
controls, but no signiﬁcant diﬀerences were
found. No signiﬁcant diﬀerences between active
and inactive disease.
not performed van Dijkhuizen
P., et al., 2018
[177]
24 JIA-ERA patients (14 with new diagnosis)
and 19 controls
no signiﬁcant diﬀerences in microbial proﬁles were
found between ERA and controls
in ERA patients:
- down-regulation of tryptophan catabolism:
metabolites of tryptophan pathway play an
immunological role by altering CD4 T cell
function and promoting development or
maintenance of inﬂammation in ERA.
Stoll ML et al.,
2016 [178]
33 JIA-ERA patients and 14 healthy controls
from India
in ERA patients:
- Abundance of Bacteroides, Enterobacteriaceae
(Klebsiella genus) and Enterococcaceae.
- Reduction of Prevotella.
not performed Aggarwal A
et al., 2017
[163]
30 JIA-ERA patients (n= 23 Caucasian, n= 3
African-American, n=2 Asian) and 19
healthy children (n= 17 Caucasian, n= 2
African-American), 11 SpA patients (n=9
Caucasian, n= 2 African-American) and
10 healthy adults (n=6 Caucasian, n= 4
African-American)
in ERA patients and in SpA adult patients:
- reduction of F. prausnitzii A2-165 strain.
in ERA patients:
- four-fold increased abundance of Bacteroides
fragilis compared to adult healthy subjects
in microbiota of ERA patients: decreased
representation of the butanoate pathway–>
reduction of SCFAs production
Stoll ML et al.,
2018 [161]
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In our recent study on Italian children [168], we compared fecal
microbiota of patients aﬀected by two diﬀerent categories of JIA (19
ERA vs 10 polyarticular-JIA) with a cohort of 29 healthy subjects. We
found that microbial biodiversity between the two JIA categories was
markedly reduced with respect to healthy subjects, suggesting a cor-
relation between disease status and biodiversity depletion, as pre-
viously reported in psoriatic arthritis and IBD patients [152,169]. Re-
garding the taxonomic diﬀerences, Ruminococcaceae were found
increased in both JIA categories, while Peptostreptococcaceae and Clos-
tridiaceae were reduced only in ERA patients, and Veillonellaceae
abundant in JIA-non ERA, consistent with previously reported data on
AS [134]. Enrichment of Clostridium genus abundance was found in
ERA patients, while in the oligo JIA a decrease in Faecalibacterium genus
was found compared to ERA and healthy subjects, though not statisti-
cally signiﬁcant. The latter ﬁnding partially diﬀers from previously
discussed Stoll's ﬁndings, where Faecalibacterium was found decreased
in ERA patients, but still remarks a possible pro-inﬂammatory role of
this component of microbiota in the pathogenesis of chronic arthritis.
We also discovered diﬀerential microbial proﬁles and intra-group
variability between active disease and remission, suggesting instability
of microbial ecosystem in autoimmune diseases with respect to healthy
status.
Interestingly, by performing prediction analysis of metabolic func-
tions, we found that JIA-ERA metagenome was diﬀerentially enriched
in bacterial functions related to cell motility and chemotaxis, suggesting
selection of potential virulence traits. These indications of enrichment
in potentially pathogenic invasiveness-related traits in JIA-ERA meta-
genome could suggest a potential improved ability of microbial com-
ponents to pass through the gastrointestinal barrier or migrate in other
districts, also responding to nutrient gradients, and activate the im-
mune responses. Moreover, given that in mice models immunogenicity
of ﬂagellin CBir1 was observed, with consequent induction of colitis,
and antibodies anti-CBir1 were found in CD patients with complicated
disease [170], we cannot exclude the potential eﬀect of ﬂagellar-as-
sembly proteins of some components of microbiota on host immune
system of JIA patients.
Furthermore, we observed diﬀerentially abundant taxa dis-
criminating for HLA-B27 status. HLA-B27 allele represents a genetic
marker strongly associated with spondyloarthropathies. At family level,
increased Lactobacillaceae in HLA-B27positive-JIA patients, and
Pasturellaceae in HLA-B27 negative-JIA patients were found. Of the
increased genera in HLA-B27 positive JIA patients, we observed
Bilophila, a sulphite-reducing bacterium known to be involved in
murine colitis [171] and in intestinal inﬂammatory disorders in humans
[172,173], via H2S production, Parvimonas, commonly observed in
periodontitis and appendicitis [174], and Oscillibacter, involved in gut
barrier integrity in mice [175], while Haemophilus and Eggerthella were
diﬀerentially enriched in HLA-B27 negative patients. When considering
only the JIA-ERA group, in addition Lactobacillus, Clostridium cluster XI,
a well-known pro-inﬂammatory and colitis inducing-bacterium, and
Dialister frequently found in periodontitis and other infections [176],
were enriched in HLA-B27 positive patients, while only Haemophilus
discriminated for HLA-B27 negative status.
In the studies discussed so far, populations were often quite het-
erogeneous, due to the variable disease duration of the patients and to
the diﬀerent therapeutic regimens. Conversely, some other studies fo-
cused only on new onset, treatment-free JIA patients.
Finally, we report results of a multicenter study conducted in Italy
and in the Netherlands, [177]. A cohort of 99 new onset, treatment–-
naïve JIA patients (78 Italians and 21 Dutch) was followed long-
itudinally with collection of samples at baseline and after one year,
which allowed to obtain fecal microbial proﬁles at diﬀerent disease
stages. JIA patients (n=99) were compared with age- and geography-
matched healthy controls (n=107). In Italian JIA children, either at
baseline or in inactive disease, enrichment of Erysipelotrichaceae and
Faecalibacterium prausnitzii and depletion of Allobaculum and
Propionibacterium acnes were observed with respect to healthy controls.
At baseline but not in inactive disease, diﬀerences in Enterococcus, Ge-
mellaceae, Parabacteroides, Ruminococcaceae and Turicibacter were
found. Whereas Bacteroides caccae, Barnesiellaceae and Dorea were dif-
ferentially enriched in inactive disease samples, but not at baseline. In
addition, Eggerthella lenta, Rikenellaceae, Coprobacillus and Mogibacter-
iaceae discriminated Dutch patients compared to healthy controls, but
no evidence of statistically signiﬁcant diﬀerences were observed. Both
in inactive and in persistent activity disease samples, microbiota rich-
ness was signiﬁcantly reduced, as previously reported by our study
[168]. No signiﬁcant diﬀerences were instead found between active and
inactive disease. The authors suppose that gut microbiota proﬁles are
associated to inﬂammation in JIA, but not to disease activity status. In
addition, this study showed diﬀerences in microbiota composition be-
tween Dutch and Italian samples, suggesting that diﬀerences in dietary
habits and other environmental factors could aﬀect the gut microbiota
composition in geographically diﬀerent populations.
Lastly, Stoll and collaborators have applied metabolomic analysis to
fecal samples of JIA to evaluate the functional potential of gut micro-
biota in inﬂammatory process [178]. A total of 24 ERA patients were
enrolled and divided into two cohorts; one of 14 patients with new
diagnosis and another of 10 children with more longstanding ERA.
Although by taxonomic analysis, no signiﬁcant diﬀerences were found
between ERA and healthy subjects, nano-liquid chromatography – mass
spectroscopy (LC-MS) analyses, performed on fecal water, demon-
strated overall a decreased variety of metabolites and altered trypto-
phan metabolomics proﬁle in both patient cohorts compared to healthy
controls. The essential amino acid tryptophan can be metabolized to a
variety of diﬀerent byproducts, some of which could be relevant for
immune responses, such as kynurenine that appears to favor the de-
velopment of regulatory T cells [179]. Down-regulation of tryptophan
metabolism, as observed in ERA patients of this study and already de-
scribed in synovial ﬂuid of patients with RA [180]. Although metabo-
lomic studies on arthritis so far are associative, alteration of tryptophan
could play an immunological role by altering CD4 T function and
promoting development or maintenance of inﬂammation in RA and
JIA-ERA. These ﬁndings are consistent with data on CARD9 deﬁcient
mice, an animal model of colitis, and in which levels of fecal indole-3-
acetic (IAA), deriving by metabolism of tryptophan, were reduced
[181]. Additionally, a study of mice with DSS- induced colitis also
showed decreased fecal IAA [182], further suggesting a contribution in
the reduction of regulatory T cells.
9. Macrophage Activation Syndrome
Macrophage Activation Syndrome (MAS) is a potentially life
threatening complication of rheumatologic diseases [183–185]. MAS is
typically associated with Systemic Juvenile Idiopathic Arthritis (SJIA);
overt symptoms are present in almost 10% of SJIA patients, while
subclinical presentation can occur in another 30–40%. MAS has been
also associated with other conditions such as pediatric Systemic Lupus
Erythematosus (pSLE) and Kawasaki Disease (KD) [186].
Clinically, the syndrome is characterized by fever, cytopenias, se-
vere hyperferritinemia, coagulopathy, liver dysfunction, and hyper-
triglyceridemia. Bone marrow biopsy often shows the presence of
macrophages with hemophagocytic activity. Many features are shared
with Hemophagocytic Lymphohistiocytosis (HLH), and MAS is indeed
classiﬁed as a secondary form of HLH [184]. In the pathophysiology of
MAS, excessive cellular activation of CD8+ T lymphocyte and macro-
phages leads to a signiﬁcant production of proinﬂammatory cytokines,
the so-called ‘cytokine storm’, which sustains a marked hyperin-
ﬂammatory state [184,185].
In a state of active disease, MAS may be triggered by infectious
agents or changes in therapy, but sometimes it is triggered without a
detectable cause.
Weaver and colleagues [163] developed a murine model of TRL9
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induced MAS by intraperitoneal administration of CpG1826 into anti-
biotic-treated and control mice, to test whether broad-spectrum anti-
biotics are protective in this condition. The model showed that germ-
free antibiotic treated mice did not develop the syndrome; disease
protection was not mediated by defective baseline TLR9 responses and
was indeed related to failed induction of myelopoiesis. Hence, such
model suggests that microbiota-dependent myelopoiesis can play a
central role in the regulation of inﬂammation, and that in the future
microbiota could be targeted for therapeutic beneﬁt for rheumatic
diseases.
Amlani and collaborators [187] reported a case of a 69-year-old
woman with antisynthetase syndrome, who developed ANCA asso-
ciated vasculitis and HLH after a fecal microbiota transplant (FMT). In
this patient, alteration of microbiota could have acted as a trigger for
both vessel inﬂammation and the development of cytokinic storm
leading to HLH, suggesting again that microbiota composition and al-
terations can aﬀect signiﬁcantly immune responses and inﬂammation.
10. Conclusions
Current evidences suggest that perturbation of gut microbiota,
dysbiosis, could contribute to development of JIA. Studies conducted so
far showed that JIA patients seem to have pro-arthritogenic microbial
proﬁles, together with a depletion of microbial biodiversity that are
clearly distinguished from microbiota of healthy subjects. Furthermore,
ﬁndings of altered functional potential of gut microbiota, such as cell
motility, ﬂagellar assembling [168], that aﬀect the gut mucosal barrier
and favor microbial dissemination, or altered metabolism of tryptophan
[178] and butanoate [161], that reduce tolerogenic immune response,
seem suggest a functional contribution of the gut microbiota to in-
ﬂammation status in JIA.
It is was hypothesized that alteration of single bacterial genus could
have direct impact on driving inﬂammation, as suggested for
Bacteroides, Akkermansia or the anti-inﬂammatory F. prausnitzii, which
is found to be depleted in ERA patients. Studies in JIA have shown to
share some features reported for other chronic immune diseases, such
as IBD and RA, strengthening the hypothesis that alteration of microbial
communities and dysbiosis, are involved in the pathogenesis of immune
mediated disorders.
However, results from JIA studies are not always completely in line
with each other; this can be explained by the fact that the populations
considered were very heterogeneous with regard to size of cohorts,
disease status and treatment and, importantly, that JIA represents a
group of many conditions with diverse clinical features, inﬂammation
and autoimmune indices. In addition, the diﬀerent geographic origins
and consequently environments and dietary habits of the studied co-
horts, not least the inter-individual variability could aﬀect the gut mi-
crobiota composition and explain the observed heterogeneity of mi-
crobial proﬁles potentially involved in JIA inﬂammation.
Despite the growing evidences of the role of dysbiosis in JIA, re-
search in this ﬁeld is only at an initial stage. So far, investigation of gut
microbiota composition and alteration in JIA compared to healthy
subjects are only descriptive and the microbial potential functional is
still predictive/hypothetical, making it diﬃcult to prove causative link
between altered microbiome and JIA. Further investigations are thus
needed to clarify the role of pro-arthritogenic microbial proﬁles and the
functional implications contributing to the inﬂammation in each JIA
category, as well as the interactions among genetics and environmental
factors concurring in the development of these pathologies. Finally,
research in this direction should include the understanding of the
possible beneﬁcial eﬀect of immunomodulatory strategies through
modiﬁcation of gut microbiota or restoration of microbial equilibrium
and maintenance of microbial biodiversity and immune homeostasis,
including the relationships with epithelial barrier function.
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